In a phase 3 trial, participants who received the shot were 29% less likely to be diagnosed with flu than those who received a conventional flu shot.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
Notably, the dual therapy group had significantly lower 28-day mortality compared to their monotherapy peers and was associated with a shorter viral shedding time.
Treatment with oseltamivir was associated with an approximately 50% reduction in the incidence of serious neuropsychiatric events.
Only a small fraction examine whether these devices or systems reduce human infections or identify potential harmful emissions.
Of 41 children, 27% died within 3 days after symptom onset, 91% of them from cerebral herniation; only 1 had been vaccinated against flu.
Of 266 pediatric flu deaths, 90% were in kids who were eligible but not fully immunized, up from 82% during the previous season.
Shipments come on the heels of a severe flu season and record deaths in children.
The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.
Secondary bacterial pneumonia rates were significantly higher in the RSV group.
The authors said the findings may help develop environmental risk alerts.
Of those at risk, 622 (32%) received an antiviral.
